BIGBEAR
PHARMACEUTICAL
Sofosbuvir and Velpatasvir Tablets represent the first all-oral, pan-genotypic single-tablet regimen for hepatitis C, indicated for patients infected with HCV genotypes 1 to 6.
AuthenticGuaranteeFast DeliveryPrivacy Urothelial carcinoma (UC) is a common type of bladder cancer, accounting for approximately 90% of all bladder cancers. About one-fifth of mUC patients···【More】
Update: 07 Apr,2026Source: BigbearViews: 95
The U.S. Food and Drug Administration (FDA) recently granted full approval to Balversa (erdafitinib) for the treatment of adult patients with locally ···【More】
Update: 07 Apr,2026Source: BigbearViews: 95
Gilead Sciences recently announced that the U.S. Food and Drug Administration (FDA) has approved an expanded pediatric indication for its hepatitis C ···【More】
Update: 03 Apr,2026Source: BigbearViews: 96
Epclusa, developed by Gilead Sciences, a leading hepatitis C treatment company, had previously received FDA approval in the United States. Epclusa is ···【More】
Update: 03 Apr,2026Source: BigbearViews: 93
The U.S. Food and Drug Administration (FDA) has approved the anti-hepatitis C drug Epclusa for the treatment of chronic hepatitis C virus (HCV) infect···【More】
Update: 03 Apr,2026Source: BigbearViews: 91
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
